2.28

7.55% 0.16

After Hours: 2.28

Atossa Therapeutics Inc (ATOS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Atossa Therapeutics Inc stock is traded at $2.28, with a volume of 227.99K. It is up +7.55% in the last 24 hours and down -48.99% over the past month. Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Previous Close:

$2.12

Open:

$2.14

24h Volume:

227.99K

Relative Volume:

1.73

Market Cap:

$22.74M

Revenue:

Net Income/Loss:

$-34.77M

P/E Ratio:

-0.6889

EPS:

-3.3097

Net Cash Flow:

$-29.79M

1W Performance:

+15.15%

1M Performance:

-48.99%

6M Performance:

-76.98%

1Y Performance:

-82.10%

1-Day Range:

$2.14

$2.41

1-Week Range:

$1.9201

$2.41

52-Week Range:

$1.70

$19.35

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name

Atossa Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

206.588.0256

Address

1448 NW MARKET STREET, SEATTLE, WA

Employee

Twitter

@atossainc

Next Earnings Date

2026-08-11

Latest SEC Filings

ATOS's Discussions on Twitter

Compare ATOS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATOS Atossa Therapeutics Inc	2.28	19.25M	0	-34.77M	-29.79M	-3.3097
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-18	Initiated	Maxim Group	Buy

Atossa Therapeutics Inc Stock (ATOS) Latest News

Jun 29, 2026

Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Price to book forward of Atossa Therapeutics, Inc. – NASDAQ:ATOS - TradingView

Jun 29, 2026

Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits

Jun 26, 2026

Atossa Therapeutics, Inc. adopts integrated biologic signals to advance breast cancer research - Traders Union

Jun 26, 2026

Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView

Jun 26, 2026

ATOS Should I Buy - Intellectia AI

Jun 26, 2026

Jun 25, 2026

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic? - simplywall.st

Jun 25, 2026

Jun 22, 2026